SCHEMBL15569376

SCHEMBL15569376

Cc1nsc(Nc2cnc3[nH]cc(C(=O)NC(C)(C)C)c3n2)n1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 1)

geneUniProtsupporting neighboursconfidence
SYK P43405 20/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15569961 0.82 SYK (1.00) SYK
SCHEMBL15569438 0.82 SYK (1.00) SYK
SCHEMBL15569686 0.80 SYK (1.00) SYK
SCHEMBL15569530 0.79 SYK (1.00) SYK
SCHEMBL15569364 0.78 SYK (1.00) SYK
SCHEMBL22067901 0.78 SYK (0.69) SYK
SCHEMBL15569819 0.77 SYK (1.00) SYK
SCHEMBL15569917 0.77 SYK (0.72) SYK
SCHEMBL15569944 0.77 SYK (1.00) SYK
SCHEMBL20125539 0.76 SYK (0.73) SYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9334278-B2 Pyrrolo[2,3-B]pyrazines as SYK inhibitors HOFFMANN-LA ROCHE INC. (US) 2016-05-10 US claimed
US-20150218170-A1 PYRROLO[2,3-B]PYRAZINES AS SYK INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2015-08-06 US claimed
EP-2888262-A1 PYRROLO[2,3-B]PYRAZINES AS SYK INHIBITORS F. Hoffmann-La Roche AG (CH) 2015-07-01 EP claimed
WO-2014029732-A1 PYRROLO[2,3-B]PYRAZINES AS SYK INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2014-02-27 WO claimed
EP-2888262-B1 PYRROLO[2,3-B]PYRAZINES AS SYK INHIBITORS HOFFMANN LA ROCHE (CH) 2018-12-19 EP disclosed
US-9334278-B2 Pyrrolo[2,3-B]pyrazines as SYK inhibitors HOFFMANN-LA ROCHE INC. (US) 2016-05-10 US disclosed
US-9334278-B2 Pyrrolo[2,3-B]pyrazines as SYK inhibitors HOFFMANN-LA ROCHE INC. (US) 2016-05-10 US disclosed
US-9334278-B2 Pyrrolo[2,3-B]pyrazines as SYK inhibitors HOFFMANN-LA ROCHE INC. (US) 2016-05-10 US disclosed
US-20150218170-A1 PYRROLO[2,3-B]PYRAZINES AS SYK INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2015-08-06 US disclosed
US-20150218170-A1 PYRROLO[2,3-B]PYRAZINES AS SYK INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2015-08-06 US disclosed
US-20150218170-A1 PYRROLO[2,3-B]PYRAZINES AS SYK INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2015-08-06 US disclosed
EP-2888262-A1 PYRROLO[2,3-B]PYRAZINES AS SYK INHIBITORS F. Hoffmann-La Roche AG (CH) 2015-07-01 EP disclosed
WO-2014029732-A1 PYRROLO[2,3-B]PYRAZINES AS SYK INHIBITORS F. HOFFMANN-LA ROCHE AG (CH) 2014-02-27 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150218170-A1 PYRROLO[2,3-B]PYRAZINES AS SYK INHIBITORS SYK, ZAP70, BTK SYK 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.